Search | Clinical Trials Finder

Conditions: Urinary Tract Infections, Bladder Cancer
Interventions: Vikor Scientific Urine-IDTM; Diagnostic Test
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Follow-up After Uterine Evacuation
Interventions: dBest semi-quantitative urine pregnancy test; Device
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ARDS, Sepsis, Pneumonia
Interventions: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan; Other · Procedure · Radiation
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Concussion
Interventions: Laboratory testing, Blood and Urine Draws; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infection
Interventions: Quantitative Interview, Ethnographic Interview, Gender Interview; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 23 Years · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 2 more

Conditions: Prostate Cancer
Interventions: MyProstateScore; Diagnostic Test
Lead sponsor: LynxDx; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Bioavailability and AUC
Interventions: Removal from study. In case of adverse event, subject treated for the AE., removal from study; Other
Lead sponsor: Vireo Systems, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Glycogen Storage Disease
Interventions: Glycogen Storage Disease markers; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Nicotine Dependence
Interventions: Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing; Device · Drug · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Dexamethasone, FDG-Positron Emission Tomography, Fludeoxyglucose F-18, Pomalidomide, Teclistamab; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 43
States / cities: Duarte, California • Irvine, California • La Jolla, California + 37 more

Conditions: Opiates, Healthy
Interventions: Vicks VapoInhaler, Poppy seeds; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix; Procedure · Other · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 214
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Hematuria - Cause Not Known
Interventions: Cxbladder Triage Plus; Diagnostic Test
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years to 88 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more

Conditions: Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
Interventions: cobas® liat CT/NG/MG nucleic acid test, Standard of Care (SOC): Clinician's Standard Practice; Diagnostic Test · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: San Francisco, California • Hamilton Square, New Jersey • Perth Amboy, New Jersey + 1 more

Conditions: Premenstrual Dysphoric Disorder (PMDD)
Interventions: sertraline 50 mg daily, Placebo Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Charlottesville, Virginia

Conditions: Amyloidosis, Primary, Cardiomyopathy
Interventions: F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET; Radiation · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test; Device
Lead sponsor: BioMérieux; Industry
Eligibility: 21 Years and older
Enrollment: 585 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Chicago, Illinois

Conditions: Hypophosphatemia, X-linked Hypophosphatemia, Renin-angiotensin System, Left Ventricular Hypertrophy
Interventions: Ang II and Ang-(1-7), FGF23 and klotho; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years to 24 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Urothelial Bladder Cancer
Interventions: CxBladder Monitor/Monitor+; Diagnostic Test
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Miami, Florida • Tampa, Florida • Charleston, South Carolina + 3 more

Conditions: Sickle Cell Anemia
Interventions: Hydroxyurea; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 24 Months to 18 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 14
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 9 more

Conditions: Metabolism; Disorder, Postprocedural, Resting Metabolic Rate, Post Operative Nutrition
Interventions: Pre-surgical nutrition, hydration, RMR, and body composition assessments, Post-surgical nutrition, hydration, RMR and body composition assessments; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 15 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Insomnia (moderate)
Interventions: GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose), Placebo, Optional Sub-Study: Neurotransmitter Urine Test; Dietary Supplement · Other · Diagnostic Test
Lead sponsor: Verb Biotics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture

The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location

The APS Phenotyping Study

Innovative Concussion Prevention Device

Engaging Care for HIV-infected Adolescent Females.

MyProstateScore Equivalency With and Without DRE

The Objective of This Study Was to Compare and Quantify the Bioavailability of Citrulline Byproducts in Blood Samples and in Urine Samples After a Single Dose of the Assigned Dietary Supplement. The Treatment Arms Containing the Following Molecules: Citrulline HCL and L-Citrulline,

Study of Glycogen Storage Disease Expression in Carriers

Nicotine Withdrawal Symptoms and Smoking Relapse

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Factors Affecting Methamphetamine and Opiates Drug Testing

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Study of Kidney Tumors in Younger Patients

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Molecular Imaging of Primary Amyloid Cardiomyopathy

VIDAS® NEPHROCLEAR Reference Interval Study

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)

Longitudinal Bladder Cancer Study for Tumour Recurrence

Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol

Changes in Resting Metabolic Rate Following Orthopedic Surgery

Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance